Cardiology News

Patients receiving daily tofacitinib doses of 10 mg for rheumatoid arthritis demonstrate an increased risk for venous thromboembolism and pulmonary embolism, compared with those taking TNF inhibitors, according to data.

Physical activity patterns dominated by vigorous exercise, housework or walking lowered stroke risk, whereas patterns with greater commuting or TV watching increased that risk, according to a prospective cohort study published in Stroke.

ATLANTA — A remote, team-based approach with immediate initiation of necessary medications improved guideline-directed medical therapy use at 6 months for patients with diabetes at high CV or renal risk, researchers reported.

ATLANTA — Among adults with mild to moderate hypertension, receiving text messages designed to cultivate spirituality was associated with an average 7 mm Hg decrease in systolic BP compared with no intervention, researchers reported.

ATLANTA — Younger women with a diagnosis of anxiety or depression are at markedly higher risk for developing conditions that increase CVD risk, such as hypertension, hyperlipidemia and diabetes, researchers reported.

Salt substitution may reduce the risk for all-cause and cardiovascular mortality, and it may also reduce the risk for major cardiovascular events, according to a systematic review and meta-analysis randomized controlled trials.

ATLANTA — New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription.

ATLANTA — A screening study presented at the American College of Cardiology Scientific Session showed that there is a high prevalence of unrecognized heart disease among former National Football League players.

The National Lipid Association updated its guidelines concerning the use of lipoprotein(a) in clinical practice, advising that there is a continuous relationship between a patient’s cardiovascular risk and their levels of Lp(a).

ATLANTA — Adults with obesity, HF with preserved ejection fraction and type 2 diabetes saw marked improvements in HF symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss.